Glancy Prongay & Murray LLP Commences Investigation on Behalf of Depomed, Inc. Investors

21:21 EDT 7 Aug 2017 | Businesswire
Glancy Prongay & Murray LLP

Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Depomed, Inc. (“Depomed” or the “Company”) (NASDAQ: DEPO) investors concerning the Company and its officers’ possible violations of federal securities laws. To obtain information or aid in the investigation, please visit the Depomed investigation page on our website at

On August 7, 2017, Demoped announced that it had received a request for information relating to the promotion of opioids from the U.S. Senate Committee on Homeland Security and Governmental Affairsas well as the Office of the Attorney General of Maryland and the U.S. Department of justice.

On this news, the Company’s stock price fell sharply in after-hours trading.

If you purchased Depomed securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to, or visit our website at If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Glancy Prongay & Murray LLP, Los Angeles/New York
Lesley Portnoy, 310-201-9150 or 888-773-9224


More From BioPortfolio on "Glancy Prongay & Murray LLP Commences Investigation on Behalf of Depomed, Inc. Investors"

Quick Search